Immuron outlines pipeline partnering push at Emerging Growth Conference

Immuron Limited (ASX: IMC; NASDAQ: IMRN) had Chief Executive Officer Steven Lydeamore present at the Emerging Growth Conference on August 19, 2026, from 4:25 to 4:35 pm U.S. Eastern Time CEO Steven Lydeamore presented at the Emerging Growth Conference on Wednesday 19th August 2026 (4:25pm – 4:35pm U.S. Eastern Time).¹

The presentation reported FY26 global sales revenue of A$7.7 million, up 6% on the prior year, with FY26 Australian sales of A$5.8 million, up 10%, FY26 U.S. sales of A$1.8 million, up 7% in Australian dollars and 13% in U.S. dollars, and FY26 Canada sales of A$0.2 million, down 55%¹. The company said cash stood at A$10.0 million, up A$7.2 million from June 30, 2025, equivalent to 22.5 months of cash used in operating activities in the first half of FY26¹, and it also received an R&D Tax Incentive payment of A$1.1 million in February 2026¹.

On clinical assets, Immuron said it decided to seek outside partners to develop and commercialize both IMM-124E and IMM-529 rather than fund them alone. It noted IMM-124E is eligible for an end of Phase 2 meeting with the U.S. FDA for traveler's diarrhea, with a Lumanity peak U.S. sales estimate of US$102 million, while IMM-529 has an FDA-approved investigational new drug application and is ready for Phase 2 trials in Clostridioides difficile infection, with a Lumanity peak U.S. sales estimate of US$400 million¹. The company said this partnering strategy removes the uncertainty of how Immuron would fund these assets through to commercialization¹ and could accelerate monetization.

Separately, the filing noted that in December 2025 Immuron entered a new research agreement backed by a U.S. Department of Defense sub-award, working with the Naval Medical Research Command and Walter Reed Army Institute of Research¹. It also disclosed that the Uniformed Services University IMM-124E trial reported topline results in December 2025, with secondary analysis still pending¹.